# Etiologies and long-term outcome of pediatric hemophagocytic lymphohistiocytosis and macrophage activation syndrome in Taiwan: a single-center retrospective study

**Authors:** Ching-Yu Wang, Jyh-Hong Lee, Ni-Chung Lee, Ya-Chiao Hu, Hsiu-Hao Chang, Li-Chieh Wang, Yu-Tsan Lin, Yao-Hsu Yang, Bor-Luen Chiang, Hsin-Hui Yu

PMC · DOI: 10.3389/fimmu.2025.1596113 · 2025-07-09

## TL;DR

This study examines the causes and outcomes of pediatric HLH and MAS in Taiwan, finding that infections and rheumatic diseases are common triggers, while malignancy is more prevalent in older children.

## Contribution

The study provides insights into the etiologies and long-term survival rates of pediatric HLH/MAS in a single-center Taiwanese cohort.

## Key findings

- Infections and rheumatic diseases are the main triggers of pediatric HLH/MAS.
- Malignancy-associated HLH is more common in adolescents and has a poor prognosis.
- M-HLH and ICU admission are significantly associated with mortality.

## Abstract

Hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are life-threatening hyperinflammatory conditions. Primary HLH is caused by genetic mutations associated with defective cytotoxicity, while secondary HLH is triggered by various factors, including infection-associated HLH (IAHS), rheumatic diseases-associated HLH (MAS), or malignancy-associated HLH (M-HLH). We retrospectively reviewed the medical records of patients younger than 20 years of age with physician-diagnosed HLH or MAS between January 2005 and July 2022 in a large medical center in Taiwan. Seven patients were prospectively enrolled since Jan 2019. Clinical and laboratory features, treatments rendered, and outcomes of patients with HLH/MAS were analyzed. Fifty-two patients with HLH/MAS were included in this study and classified as follows: 21 (40.4%) with IAHS, 20 (38.5%) with MAS, 5 (9.6%) with M-HLH, 4 (7.7%) with primary HLH, and 2 (3.8%) with unclassified HLH (U-HLH). The median age of diagnosis for all patients was 9.04 years, while it ranged between 5.12 (for primary HLH) to 16.03 (for M-HLH) years. Two-year probabilities of survival of each group of HLH/MAS were 100%, 85.7%, 65.63%, 25%, and 20% for patients with U-HLH, IAHS, MAS, primary HLH, and M-HLH, respectively (log-rank, P =0.0018). The five-year probability of survival was 65.63% for patients with MAS. M-HLH and ICU admission were significantly associated with mortality. Infections and rheumatic diseases are the main triggers or conditions associated with pediatric HLH/MAS, whereas malignancy is an important etiology among adolescents.

## Linked entities

- **Diseases:** hemophagocytic lymphohistiocytosis (MONDO:0015540), macrophage activation syndrome (MONDO:0015545)

## Full-text entities

- **Diseases:** Hemophagocytic lymphohistiocytosis (MESH:D051359), Infections (MESH:D007239), cytotoxicity (MESH:D064420), rheumatic diseases (MESH:D012216), MAS (MESH:D055501), malignancy (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12284797/full.md

---
Source: https://tomesphere.com/paper/PMC12284797